12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bridion sugammadex: Phase III completed

Merck disclosed in its 3Q12 earnings that it completed a double-blind, placebo-controlled Phase III trial comparing 4 mg/kg IV sugammadex vs. the usual care of neostigmine or spontaneous recovery in 1,198 patients receiving thromboprophylaxis and undergoing hip fracture surgery or joint replacement. The pharma expects to present data from the trial...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >